Drug Trial Radar · NCT06208241
Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Jul 12, 2023
Primary completion
Sep 25, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Amir OronAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Enlivex Therapeutics Ltd.
- First posted
- Jan 17, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a pilot study to assess safety and possible efficacy of Allocetra-OTS in end-stage knee osteoarthritis.
Conditions
- Knee Osteoarthritis
Interventions
Allocetra-OTSDrug
Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events and Serious adverse events following Allocetra-OTS injectionTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kaplan Medical Center
Rehovot, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.